The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

R D'Haens, Geert; Panaccione, Remo; D R Higgins, Peter; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; B Hanauer, Stephen; Herfarth, Hans; W Hommes, Daan; Kamm, Michael; Löfberg, Robert; Quary, A; Sands, Bruce; Sood, A; Watermeyer, G; Watermayer, G; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan; Siegel, Corey; Targan, Stephen; Watanabe, M; Feagan, Brian; J Sandborn, William; Frédéric Colombel, Jean; Travis, Simon

doi:10.1038/ajg.2010.392

Public

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Shared by NobleBlocks on Feb 1, 2011 • 12:00 AM UTC

Authors:

Geert R D'Haens

Remo Panaccione

Peter D R Higgins

Abstract

The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimburse...

Discussions